The Sanford Project & DiaMedica to Present Preclinical Abstract on DM-199 Treatment of Type 1 Diabetes at the 73rd Annual ADA Conference

SIOUX FALLS, SOUTH DAKOTA and MINNEAPOLIS, MINNESOTA--(Marketwired - June 20, 2013) - The Sanford Project & DiaMedica (TSX VENTURE:DMA), announced today that their abstract titled "Human Tissue Kallikrein (DM-199 Compound) Induces Diabetes-Protective Immunomodulation in NOD Mouse T1D Model," has been selected for a Late Breaking Poster Presentation at the American Diabetes Association's (ADA) 73^rd Scientific Sessions, being held on June 21-25 in Chicago, Illinois. The poster presentation describes DM-199's mechanism of action in modulating immunological parameters associated with developing diabetes when administered to non-obese diabetic (NOD) mice.

The poster will be presented by Dr. Alexei Savinov, Associate Scientist at The Sanford Project and has been assigned presentation number 56-LB in category 01-E Clinical Therapeutics/New Technology - Non Insulin Injectable. Dr. Savinov is scheduled to present the poster on Sunday, June 23, 2013 from 12:00 PM - 2:00 PM.

DiaMedica also announces that the Board of Directors has, subject to TSX Venture Exchange approval, authorized amending the exercise price of the outstanding warrants issued on May 8, 2012 in connection with DiaMedica's early exercise incentive program from $2.50 to $1.60. All other terms of such warrants will remain the same.

About The Sanford Project

The Sanford Project is one of the four initiatives made possible through Denny Sanford's transformational gift to Sanford Health in 2007. From its inception, The Sanford Project was "designed for results." Sanford Health will combine clinical components of patient care and science into one of the most promising and fast-moving fields of research; regenerative medicine. Their goal is to research and cure Type 1 diabetes, all in pursuit of a healthy future for our children. For further information please visit www.sanfordproject.org.

About DiaMedica

DiaMedica Inc. is a publicly traded (TSX VENTURE:DMA) clinical stage biopharmaceutical company focused on the discovery and development of novel therapies to treat diabetes and the complications associated with diabetes. DiaMedica's lead clinical stage compound, DM-199, is a recombinant human protein that represents a novel approach to treating Type 1 and Type 2 diabetes. DiaMedica is also developing a novel monoclonal antibody, DM-204 for the treatment of Type 2 diabetes which is in preclinical development.

The Company is listed on the TSX Venture Exchange in Canada under the trading symbol 'DMA'.

FORWARD-LOOKING STATEMENTS
The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.